LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Frigout, Yvann"
  2. AU="Cataldi, Rodrigo Lessa"

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Transition from child to adult health care for patients with lysosomal storage diseases in France: current status and priorities-the TENALYS study, a patient perspective survey.

    Genevaz, Delphine / Arnoux, Armelle / Marcel, Catherine / Brassier, Anaïs / Pichard, Samia / Feillet, François / Labarthe, François / Chabrol, Brigitte / Berger, Marc / Lapointe, Anne-Sophie / Frigout, Yvann / Héron, Bénédicte / Chatellier, Gilles / Belmatoug, Nadia

    Orphanet journal of rare diseases

    2022  Volume 17, Issue 1, Page(s) 68

    Abstract: Background: Transition from childhood to adulthood (TCA) is usually difficult in rare, progressive and multisystemic diseases. New treatments and modalities of care for many lysosomal diseases (LD) can increase life expectancy, and a successful TCA can ... ...

    Abstract Background: Transition from childhood to adulthood (TCA) is usually difficult in rare, progressive and multisystemic diseases. New treatments and modalities of care for many lysosomal diseases (LD) can increase life expectancy, and a successful TCA can help patient who reach adulthood to avoid disruption to health care. In France, some TCA initiatives have been taken by referral centers but in view of the problems encountered by Vaincre les Maladies Lysosomales (VML), the LD patient association, they seem to be insufficient. The aim of this study is to determine the current state of the TCA process and to identify actions to improve it through interviews with patient families and physicians in LD referral centers. The study is based upon an observational, non-interventional, cross-sectional, national survey which used two anonymous questionnaires. These questionnaires, developed by a scientific committee including representatives from VML and medical specialists in LD, were sent to patients who were receiving care in pediatric departments at age 15 years or older. Questionnaires were also sent to their referral pediatricians.
    Results: Fifty-four patients were included. Forty-two questionnaires were completed by patients and their corresponding physicians and 12 were completed by physicians only. The majority of the patients (80%) were informed that transfer to adult healthcare would occur, but 52% were informed after their eighteenth birthday. Forty-eight percent indicated that they were informed that a TCA coordinator would be appointed; for 39% the time frame for the transfer was communicated, and 31% were informed of the composition of the adult medical team. Among the actions that patients rated as "important/very important", and considered to be a priority in their comments, the most frequently cited were the provision of explanatory documents on the TCA (94%), the transmission of the medical file from the pediatric sector to the adult sector (94%) and a joint consultation with both pediatrician and adult unit physician (91%). Physicians were in agreement concerning the primary importance of the last two actions.
    Conclusion: This study provides a basis for the deployment, on the national level, of transition programs which include specific actions that patients view as priorities.
    MeSH term(s) Adolescent ; Adult ; Child ; Cross-Sectional Studies ; Delivery of Health Care ; France ; Humans ; Lysosomal Storage Diseases/therapy ; Surveys and Questionnaires ; Young Adult
    Language English
    Publishing date 2022-02-21
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2225857-7
    ISSN 1750-1172 ; 1750-1172
    ISSN (online) 1750-1172
    ISSN 1750-1172
    DOI 10.1186/s13023-022-02232-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Similar Gut Hormone Secretions Two Years After One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass: a Pilot Study.

    De Bandt, David / Rives-Lange, Claire / Frigout, Yvann / Bergerot, Damien / Blanchard, Anne / Le Gall, Maude / Lacorte, Jean-Marc / Chevallier, Jean-Marc / Czernichow, Sébastien / Poghosyan, Tigran / Carette, Claire / Le Beyec, Johanne

    Obesity surgery

    2022  Volume 32, Issue 3, Page(s) 757–762

    Abstract: Objectives: One-anastomosis gastric bypass (OAGB) is as effective as Roux-en-Y gastric bypass (RYGB) regarding weight loss and diabetes remission. However, there are no data on gut hormone secretions after OAGB. The aim of this study was to compare ... ...

    Abstract Objectives: One-anastomosis gastric bypass (OAGB) is as effective as Roux-en-Y gastric bypass (RYGB) regarding weight loss and diabetes remission. However, there are no data on gut hormone secretions after OAGB. The aim of this study was to compare fasting and postprandial secretions of gut and pancreatic hormones in OAGB versus RYGB patients.
    Design and methods: Twenty-nine patients, 16 OAGB- and 13 RYGB-operated, underwent a liquid mixed-meal tolerance test at 2 years' post-surgery. Blood was sampled before and 15, 30, 60, 90, and 120 min after meal for plasma measurement of glucose, C-peptide, insulin, glucagon, GLP-1, GIP, GLP-2, PYY, and ghrelin.
    Results: Percentage of total weight loss 2 years post-surgery were -33.9 ± 1.8% for OAGB and -31.2 ± 1.6% for RYGB (p = 0.6). Four patients with persistent diabetes were excluded for further analysis. Fasting and postprandial glucose levels (peaks and area under curve values) were similar between groups. HOMA index was lower in the OAGB group (0.8 ± 0.1 vs 1.3 ± 0.2 in RYGB, p < 0.05). Levels of C-peptide (or insulin) measured at 30 min were significantly lower in OAGB vs RYGB patients (6.9 ± 0.5 vs 9.7 ± 1.1 µg/l, p < 0.05). No difference was observed between OAGB and RYGB groups for GLP-1, GLP-2, PYY, or ghrelin postprandial secretions, but GIP tended to be lower in OAGB vs RYGB patients (756 ± 155 vs 1100 ± 188 pg/ml for postprandial peak concentrations, p = 0.06).
    Conclusions: This is the first clinical study showing that OAGB procedure, like RYGB, results in high postprandial secretions of gut hormones, in particular GLP-1.
    Trial registration: Clinical Trials NCT03482895.
    MeSH term(s) Anastomosis, Roux-en-Y/methods ; Blood Glucose/analysis ; C-Peptide ; Gastric Bypass/methods ; Ghrelin ; Glucagon-Like Peptide 1 ; Glucose ; Humans ; Insulin ; Obesity, Morbid/surgery ; Pilot Projects ; Weight Loss
    Chemical Substances Blood Glucose ; C-Peptide ; Ghrelin ; Insulin ; Glucagon-Like Peptide 1 (89750-14-1) ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2022-01-07
    Publishing country United States
    Document type Clinical Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1070827-3
    ISSN 1708-0428 ; 0960-8923
    ISSN (online) 1708-0428
    ISSN 0960-8923
    DOI 10.1007/s11695-021-05837-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism.

    Marcos-Contreras, Oscar A / Martinez de Lizarrondo, Sara / Bardou, Isabelle / Orset, Cyrille / Pruvost, Mathilde / Anfray, Antoine / Frigout, Yvann / Hommet, Yannick / Lebouvier, Laurent / Montaner, Joan / Vivien, Denis / Gauberti, Maxime

    Blood

    2016  Volume 128, Issue 20, Page(s) 2423–2434

    Abstract: Hyperfibrinolysis is a systemic condition occurring in various clinical disorders such as trauma, liver cirrhosis, and leukemia. Apart from increased bleeding tendency, the pathophysiological consequences of hyperfibrinolysis remain largely unknown. Our ... ...

    Abstract Hyperfibrinolysis is a systemic condition occurring in various clinical disorders such as trauma, liver cirrhosis, and leukemia. Apart from increased bleeding tendency, the pathophysiological consequences of hyperfibrinolysis remain largely unknown. Our aim was to develop an experimental model of hyperfibrinolysis and to study its effects on the homeostasis of the blood-brain barrier (BBB). We induced a sustained hyperfibrinolytic state in mice by hydrodynamic transfection of a plasmid encoding for tissue-type plasminogen activator (tPA). As revealed by near-infrared fluorescence imaging, hyperfibrinolytic mice presented a significant increase in BBB permeability. Using a set of deletion variants of tPA and pharmacological approaches, we demonstrated that this effect was independent of N-methyl-D-aspartate receptor, low-density lipoprotein-related protein, protease-activated receptor-1, or matrix metalloproteinases. In contrast, we provide evidence that hyperfibrinolysis-induced BBB leakage is dependent on plasmin-mediated generation of bradykinin and subsequent activation of bradykinin B2 receptors. Accordingly, this effect was prevented by icatibant, a clinically available B2 receptor antagonist. In agreement with these preclinical data, bradykinin generation was also observed in humans in a context of acute pharmacological hyperfibrinolysis. Altogether, these results suggest that B2 receptor blockade may be a promising strategy to prevent the deleterious effects of hyperfibrinolysis on the homeostasis of the BBB.
    MeSH term(s) Animals ; Blood-Brain Barrier/drug effects ; Blood-Brain Barrier/metabolism ; Bradykinin/metabolism ; Bradykinin/physiology ; Bradykinin B2 Receptor Antagonists/pharmacology ; Brain/drug effects ; Brain/metabolism ; Capillary Permeability/drug effects ; Capillary Permeability/genetics ; Capillary Permeability/physiology ; Fibrinolysin/metabolism ; Fibrinolysin/physiology ; Fibrinolysis/drug effects ; Fibrinolysis/genetics ; Fibrinolysis/physiology ; Hydrodynamics ; Mice ; Mice, Transgenic ; Receptor, Bradykinin B2/genetics ; Receptor, Bradykinin B2/metabolism ; Signal Transduction/drug effects ; Signal Transduction/genetics ; Tissue Plasminogen Activator/genetics ; Tissue Plasminogen Activator/metabolism
    Chemical Substances Bradykinin B2 Receptor Antagonists ; Receptor, Bradykinin B2 ; Tissue Plasminogen Activator (EC 3.4.21.68) ; Fibrinolysin (EC 3.4.21.7) ; Bradykinin (S8TIM42R2W)
    Language English
    Publishing date 2016-08-16
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2016-03-705384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top